MainboardNSELISTED
ESDS Software IPO
₹408 – ₹408 · Issue Size ₹720 CrIPO Overview
Business Model
Competitive Advantages
- We are a leading player offering end-to-end cloud, managed services, Data Centre infrastructure and software
- Among Indian players, we were one of the early adopters of cloud technology in India (source: Nexdigm Report),
- Centre infrastructure and software solutions, we are one of the only two players providing the entire spectrum of
- This includes community clouds tailored for industries such as:
IPO Timeline
Listing Performance
Risk Factors
MUFG Intime Indialow
Private Limited (formerly known as Link Intime India Private Limited)
Strengths & Weaknesses
Strengths
- We are a leading player offering end-to-end cloud, managed services, Data Centre infrastructure and software
- Among Indian players, we were one of the early adopters of cloud technology in India (source: Nexdigm Report),
- Centre infrastructure and software solutions, we are one of the only two players providing the entire spectrum of
- This includes community clouds tailored for industries such as:
Weaknesses
- MUFG Intime India
Management & Promoters
P
Piyush Prakashchandra SomaniManaging Director
I
Indian CompaniesIndependent Director
K
Komal Piyush SomaniWhole-time Director
F
Foreign CompaniesIndependent Director
J
Jitendra PathakDirector
T
Thandankorai Ganapathy DhandapaniIndependent Director
P
Pamela KumarIndependent Director
V
Venkatesh NatarajanIndependent Director
A
Ashok Leyland Information Management Services.Director
N
No. Category ParticularsWhole-time Director
Peer Comparison
| Company | P/E | EPS |
|---|---|---|
| ESDS Software IPO | — | — |
| For more details see "Our Business – Competition" on page | — | — |
| We are committed to transitioning our operations to renewabl | 32.0x | — |
Pre-IPO Financials
| Period | Revenue (Cr) | PAT (Cr) | Net Worth (Cr) | Total Assets (Cr) |
|---|---|---|---|---|
| September 2024 | — | ₹0.3 Cr | ₹0.2 Cr | ₹3.1 Cr |
| March 2024 | — | ₹2.4 Cr | ₹0.3 Cr | ₹202.4 Cr |
| March 2023 | — | ₹202.5 Cr | — | ₹3.1 Cr |
| March 2022 | — | ₹0.4 Cr | — | ₹202.4 Cr |
About
Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medica
| Exchange | NSE |
| Issue Type | mainboard |
| Face Value | ₹1 per share |
Documents
rupiya.io is for research and education only. IPO data is sourced from public disclosures (DRHP/RHP). Not investment advice. Validate with SEBI-regulated disclosures before acting.